Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage II Malignant Mesothelioma Clear all
Terminated Phase 2Phase 3 Interventional Results available

Nintedanib (BIBF 1120) in Mesothelioma

NCT01907100
View directory record Official record
Conditions
Mesothelioma
Interventions
Nintedanib, Pemetrexed, Cisplatin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

NCT01112293
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
GC1008
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

NCT01503177
View directory record Official record
Conditions
Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
Interventions
oncolytic measles virus encoding thyroidal sodium iodide symporter, laboratory biomarker analysis, single photon emission computed tomography, computed tomography
Biological · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

NCT00003723
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 6, 2026, 5:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

NCT00604461
View directory record Official record
Conditions
Mesothelioma
Interventions
Carboplatin, Bevacizumab and Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 6, 2026, 5:45 PM EDT
Suspended Phase 1Phase 2 Interventional

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

NCT05703854
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
Interventions
CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 6, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Mithramycin for Lung, Esophagus, and Other Chest Cancers

NCT01624090
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms, Breast Cancer
Interventions
Mithramycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 6, 2026, 5:45 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

NCT00281125
View directory record Official record
Conditions
Non-Small Cell Lung Cancer and Pleural Mesothelioma
Interventions
PTK787 and Pemetrexed with or without Cisplatin
Drug
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 6, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

NCT00165503
View directory record Official record
Conditions
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions
Cisplatin, Sodium Thiosulfate, ALIMTA
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Malignant Mesothelioma

NCT02399371
View directory record Official record
Conditions
Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Sarcomatoid Mesothelioma
Interventions
Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study
Biological · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

NCT00004547
View directory record Official record
Conditions
Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
Interventions
Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

NCT00017186
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
epirubicin hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 6, 2026, 5:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

NCT01583686
View directory record Official record
Conditions
Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer
Interventions
Fludarabine, Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL), Cyclophosphamide, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 6, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

NCT03644550
View directory record Official record
Conditions
Mesothelioma
Interventions
LMB-100, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

NCT00243074
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
cediranib maleate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

NCT02899195
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma
Interventions
Durvalumab
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 6, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

NCT00003508
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
1 Year to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

NCT00107432
View directory record Official record
Conditions
Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

NCT02568449
View directory record Official record
Conditions
Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma
Interventions
Nintedanib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 6, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

NCT02293005
View directory record Official record
Conditions
Lung Cancer, Mesothelioma
Interventions
Alisertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 6, 2026, 5:45 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

NCT03228537
View directory record Official record
Conditions
Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
Interventions
Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
174
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 6, 2026, 5:45 PM EDT
Recruiting Phase 2 Interventional

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 6, 2026, 5:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

NCT01064648
View directory record Official record
Conditions
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
Interventions
Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
230
States / cities
Rogers, Arkansas • Antioch, California • Burbank, California + 148 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 5:45 PM EDT